Form 4: ProMIS CDO Acquires Shares, Warrants in Key Transaction

ProMIS Neurosciences' Chief Development Officer, Johanne Kaplan, acquired 2,060 common shares and an equal number of warrants as part of a securities purchase agreement.

Summary

• Johanne Kaplan, Chief Development Officer of ProMIS Neurosciences Inc., acquired 2,060 common shares and 2,060 common share purchase warrants on February 3, 2026.
• The acquisition was made pursuant to a Securities Purchase Agreement entered into by the Company with selected investors.
• The purchase price for each common share and common share warrant was $12.13.
• Following this transaction, Ms. Kaplan beneficially owns 2,312 common shares and 2,060 common share warrants.
• The common share warrants have an exercise price of $14.4 and will expire upon the earlier of February 3, 2031, or within 60 days of the public announcement of topline data from cohorts treated with single ascending doses of PMN310.
• A one-for-twenty-five reverse stock split of the Company's Common Shares was effected on November 28, 2025, which impacts the reported share counts.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as a key executive's increased stake suggests confidence in the company's future, particularly its PMN310 development program.

Positives

• An insider, the Chief Development Officer, is increasing their direct ownership in the company, which can signal confidence in future prospects and the company's drug development pipeline.
• The acquisition was part of a broader Securities Purchase Agreement, suggesting other investors also participated, potentially indicating broader market interest in the company.

Risks

• The expiration of common share warrants is tied to the announcement of topline data from PMN310 cohorts, introducing a dependency on the successful outcome and timely release of clinical trial results.

Future Outlook

The expiration of the common share warrants is linked to the public announcement of topline data from cohorts treated with single ascending doses of PMN310, indicating a future milestone related to the company's drug development pipeline.

Industry Context

StockSavvy.ai notes that insider purchases, especially by key development officers in biotechnology firms like ProMIS Neurosciences, can be interpreted by the market as a positive signal regarding the company's drug pipeline and future prospects. This is particularly relevant given the mention of PMN310 clinical data as a warrant expiration trigger, highlighting the importance of R&D milestones in the biotech sector.

Related Party Transactions

• The acquisition of shares and warrants by Johanne Kaplan, Chief Development Officer, from ProMIS Neurosciences Inc. constitutes a related party transaction as she is an officer of the company.

Stakeholder Impact

• Shareholders may view the insider purchase as a positive sign of management confidence, potentially influencing investor sentiment.

Next Steps

• Public announcement of topline data from cohorts treated with single ascending doses of PMN310, which will trigger the earlier expiration of the common share warrants.

Key Dates

Recommendation

While the insider purchase by the Chief Development Officer is a positive indicator of management confidence, particularly in the PMN310 program, it is a single transaction. The broader context of the company's financial health, the impact of the recent reverse stock split, and the progress of its clinical pipeline would require a more comprehensive analysis beyond this Form 4 filing to warrant a 'buy' recommendation. For now, it suggests maintaining existing positions while awaiting further operational updates.

Keywords

ProMIS Neurosciences, PMN, Insider Trading, Form 4, Johanne Kaplan, Chief Development Officer, Common Shares, Warrants, Securities Purchase Agreement, Reverse Stock Split, PMN310